ifosfamide has been researched along with Urinary Tract Diseases in 17 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed." | 7.68 | Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993) |
| "The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990." | 7.68 | Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993) |
| "Ifosfamide is a cyclophosphamide analogue synthesized in the 1960s with antineoplastic activity demonstrated in early broad-ranging phase I studies conducted in Germany in the 1970s." | 6.38 | Ifosfamide and mesna in epithelial ovarian carcinoma. ( Sutton, G, 1993) |
| "In a phase II trial of ifosfamide 2 g/m2 days 1 to 4 with mesna uroprotection in 124 patients who had previously failed treatment for sarcomas, 3% achieved a complete response (CR), and 18% had a CR or partial response (PR)." | 5.06 | Dana-Farber Cancer Institute studies in advanced sarcoma. ( Antman, KH; Elias, A, 1990) |
| "Two trials using ifosfamide-based combination chemotherapy for advanced soft-tissue sarcoma have been completed." | 3.68 | Ifosfamide combination regimens for soft-tissue sarcoma. ( Bell, DR; Dalley, D; Levi, J; Simes, RJ; Stuart-Harris, R; Wiltshaw, E, 1993) |
| "The response of ifosfamide-based chemotherapeutic regimens was retrospectively analyzed in adult patients with advanced soft-tissue sarcoma who were treated at the West German Tumor Center, Essen, between 1978 and 1990." | 3.68 | Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen. ( Kellner, R; Schütte, J; Seeber, S, 1993) |
| "Ifosfamide was administered by intravenous drip infusion at a daily dose of 2 g/m2 for 5 consecutive days, and mesna was intravenously administered at 20% of the ifosfamide dose, three times daily for 5 consecutive days." | 2.67 | Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders. ( Fukuoka, M; Furuse, K; Ikegami, H; Kawahara, M; Kodama, N; Masuda, N; Nakamura, S; Negoro, S; Nishio, H; Ohnoshi, T, 1991) |
| "Ifosfamide is a cyclophosphamide analogue synthesized in the 1960s with antineoplastic activity demonstrated in early broad-ranging phase I studies conducted in Germany in the 1970s." | 2.38 | Ifosfamide and mesna in epithelial ovarian carcinoma. ( Sutton, G, 1993) |
| "One hundred and forty-six patients with advanced malignant disease were treated with 6 different dosage schedules of ifosfamide (IFX)." | 1.28 | Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector. ( Falkson, CI; Falkson, G; Falkson, HC, 1989) |
| "Ifosfamide was given to 61 patients with malignant solid tumors diagnosed before the age of 21 years." | 1.27 | Phase II trial of ifosfamide in children with malignant solid tumors. ( Douglass, EC; Etcubanas, E; Green, AA; Hayes, FA; Horowitz, ME; Meyer, WH; Pratt, CB; Thompson, EI; Wilimas, JA, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 8 (47.06) | 18.7374 |
| 1990's | 8 (47.06) | 18.2507 |
| 2000's | 1 (5.88) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lawson, M | 1 |
| Vasilaras, A | 1 |
| De Vries, A | 1 |
| Mactaggart, P | 1 |
| Nicol, D | 1 |
| Brock, N | 4 |
| Pohl, J | 3 |
| Stekar, J | 3 |
| Sutton, G | 1 |
| Cerny, T | 1 |
| Stuart-Harris, R | 1 |
| Dalley, D | 1 |
| Bell, DR | 1 |
| Levi, J | 1 |
| Simes, RJ | 1 |
| Wiltshaw, E | 1 |
| Schütte, J | 1 |
| Kellner, R | 1 |
| Seeber, S | 1 |
| Niemeyer, U | 1 |
| Scheffler, G | 1 |
| Munshi, NC | 1 |
| Loehrer, PJ | 2 |
| Williams, SD | 1 |
| Fukuoka, M | 1 |
| Negoro, S | 1 |
| Masuda, N | 1 |
| Furuse, K | 1 |
| Kawahara, M | 1 |
| Kodama, N | 1 |
| Ikegami, H | 1 |
| Nakamura, S | 1 |
| Nishio, H | 1 |
| Ohnoshi, T | 1 |
| Antman, KH | 1 |
| Elias, A | 1 |
| Holoye, PY | 1 |
| Glisson, BS | 1 |
| Lee, JS | 1 |
| Dhingra, HM | 1 |
| Murphy, WK | 1 |
| Umsawasdi, T | 1 |
| Levy, JK | 1 |
| Jeffries, D | 1 |
| Raber, MN | 1 |
| Hong, WK | 1 |
| Falkson, CI | 1 |
| Falkson, HC | 1 |
| Falkson, G | 1 |
| Ishikawa, M | 1 |
| Takayanagi, Y | 1 |
| Sasaki, K | 1 |
| Pratt, CB | 1 |
| Horowitz, ME | 1 |
| Meyer, WH | 1 |
| Etcubanas, E | 1 |
| Thompson, EI | 1 |
| Douglass, EC | 1 |
| Wilimas, JA | 1 |
| Hayes, FA | 1 |
| Green, AA | 1 |
| Einhorn, LH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase Ⅱ Randomized Clinical Trial Comparing Vinorelbine-ifosfamide With Gefitinib as Third-line Treatment in Advanced EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients[NCT01749072] | Phase 2 | 120 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for ifosfamide and Urinary Tract Diseases
| Article | Year |
|---|---|
Urological implications of cyclophosphamide and ifosfamide.
Topics: Antineoplastic Agents; Carcinoma, Transitional Cell; Cyclophosphamide; Cystitis; Humans; Ifosfamide; | 2008 |
Ifosfamide and mesna in epithelial ovarian carcinoma.
Topics: Carcinoma; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Female; Humans; | 1993 |
Uroprotection in patients receiving cyclophosphamide and ifosfamide.
Topics: Acrolein; Cyclophosphamide; Humans; Ifosfamide; Sulfhydryl Compounds; Urinary Tract; Urologic Diseas | 1991 |
2 trials available for ifosfamide and Urinary Tract Diseases
| Article | Year |
|---|---|
Placebo-controlled double-blind comparative study on the preventive efficacy of mesna against ifosfamide-induced urinary disorders.
Topics: Adult; Aged; Double-Blind Method; Female; Hematuria; Humans; Ifosfamide; Lung Neoplasms; Male; Mesna | 1991 |
Dana-Farber Cancer Institute studies in advanced sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation | 1990 |
12 other studies available for ifosfamide and Urinary Tract Diseases
| Article | Year |
|---|---|
The development of mesna for the inhibition of urotoxic side effects of cyclophosphamide, ifosfamide, and other oxazaphosphorine cytostatics.
Topics: Animals; Antineoplastic Agents; Cyclophosphamide; Cystitis; Erythrocyte Count; Ifosfamide; Mercaptoe | 1980 |
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention. 2. Comparative study on the uroprotective efficacy of thiols and other sulfur compounds.
Topics: Animals; Cyclophosphamide; Cystitis; Female; Hemorrhage; Ifosfamide; Kinetics; Male; Rats; Rats, Inb | 1981 |
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--I. Experimental studies on the urotoxicity of alkylating compounds.
Topics: Alkylating Agents; Animals; Cyclophosphamide; Cystitis; Dose-Response Relationship, Drug; Female; If | 1981 |
High dose ifosfamide with mesna uroprotection.
Topics: Drug Therapy, Combination; Humans; Ifosfamide; Lymphoma; Mesna; Urologic Diseases | 1993 |
Ifosfamide combination regimens for soft-tissue sarcoma.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Etoposide; Fem | 1993 |
Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Dru | 1993 |
Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
Topics: Acrolein; Aldehydes; Animals; Cyclophosphamide; Cystitis; Female; Ifosfamide; Inactivation, Metaboli | 1979 |
Ifosfamide with mesna uroprotection in the management of lung cancer.
Topics: Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Female; Humans | 1990 |
Ifosfamide and mesna in the treatment of malignant disease mesna as urothelial protector.
Topics: Adult; Aged; Drug Therapy, Combination; Female; Humans; Ifosfamide; Male; Mercaptoethanol; Mesna; Mi | 1989 |
Influence of buthionine sulfoximine on the lethality of ifosfamide and ifosfamide-induced urotoxicity in mice.
Topics: Animals; Buthionine Sulfoximine; Cysteamine; Glutathione; Ifosfamide; Liver; Male; Methionine Sulfox | 1989 |
Phase II trial of ifosfamide in children with malignant solid tumors.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Drug Eva | 1987 |
Ifosfamide chemotherapy for pancreatic carcinoma.
Topics: Acetylcysteine; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Ifosfam | 1986 |